A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

Clinical trial NCT00271765 · COMPLETED

Trial details

NCT number

NCT00271765

Sponsor

Inotek Pharmaceuticals Corporation

Status

COMPLETED

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2004-01-01

Enrollment

40

View on ClinicalTrials.gov